

JÃ©rÃ©me Avouac

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3574938/publications.pdf>

Version: 2024-02-01

182
papers

8,847
citations

34016

52
h-index

51492

86
g-index

195
all docs

195
docs citations

195
times ranked

8793
citing authors

#	ARTICLE	IF	CITATIONS
1	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
2	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
3	Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. <i>Rheumatology</i> , 2012, 51, 1017-1026.	0.9	345
4	Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 476-481.	0.5	330
5	Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies. <i>Journal of Rheumatology</i> , 2010, 37, 2290-2298.	1.0	259
6	Osteoarthritis of the knee and hip and activity: a systematic international review and synthesis (OASIS). <i>Joint Bone Spine</i> , 2006, 73, 442-455.	0.8	216
7	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	2.2	211
8	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. <i>PLoS Genetics</i> , 2011, 7, e1002091.	1.5	205
9	Cardiac involvement in systemic sclerosis assessed by tissue Doppler echocardiography during routine care: A controlled study of 100 consecutive patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 1803-1809.	6.7	171
10	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	1.0	161
11	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1217-1220.	0.5	160
12	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
13	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2724-2733.	6.7	133
14	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
15	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1009-1015.	0.5	112
16	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.5	111
17	Performance of Candidate Serum Biomarkers for Systemic Sclerosis-associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 972-982.	2.9	101
18	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.5	93

#	ARTICLE	IF	CITATIONS
19	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 115-123.	1.6	84
20	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.5	82
21	Inhibition of activator protein 1 signaling abrogates transforming growth factor β -mediated activation of fibroblasts and prevents experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1642-1652.	6.7	81
22	Targeting synovial neoangiogenesis in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2017, 16, 594-601.	2.5	80
23	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF- β signalling to prevent fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1215-1222.	0.5	78
24	Articular involvement in systemic sclerosis. <i>Rheumatology</i> , 2012, 51, 1347-1356.	0.9	76
25	Associated Autoimmune Diseases in Systemic Sclerosis Define a Subset of Patients with Milder Disease: Results from 2 Large Cohorts of European Caucasian Patients. <i>Journal of Rheumatology</i> , 2010, 37, 608-614.	1.0	73
26	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 800-809.	6.7	73
27	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 99-105.	1.0	73
28	Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 86-94.	1.6	71
29	Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e37-e37.	0.5	71
30	Increased risk of osteoporosis and fracture in women with systemic sclerosis: A comparative study with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1871-1878.	1.5	68
31	Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. <i>Arthritis Research and Therapy</i> , 2014, 16, R157.	1.6	68
32	Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2175-2183.	0.5	68
33	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1931-1940.	0.5	67
34	Regulatory T Cells in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 2356.	2.2	67
35	High DNA Oxidative Damage in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2540-2547.	1.0	64
36	Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. <i>Journal of Rheumatology</i> , 2014, 41, 2395-2402.	1.0	63

#	ARTICLE	IF	CITATIONS
37	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 149, 1482-1493.	0.4	63
38	Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 741-748.	1.6	63
39	Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R55.	1.6	62
40	Systemic sclerosis at the crossroad of polyautoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 1052-1057.	2.5	62
41	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
42	The transcription factor JunD mediates transforming growth factor β -induced fibroblast activation and fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1320-1326.	0.5	59
43	Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1481-1485.	1.0	57
44	Hand and Wrist Involvement in Systemic Sclerosis: US Features. <i>Radiology</i> , 2013, 269, 824-830.	3.6	57
45	Inflammation and Disease Activity are Associated with High Circulating Cardiac Markers in Rheumatoid Arthritis Independently of Traditional Cardiovascular Risk Factors. <i>Journal of Rheumatology</i> , 2014, 41, 248-255.	1.0	56
46	Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2142-2149.	0.5	56
47	Systemic sclerosis: an update in 2008. <i>Joint Bone Spine</i> , 2008, 75, 650-655.	0.8	54
48	Phenotype-Haplotype Correlation of <i>IRF5</i> in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. <i>Journal of Rheumatology</i> , 2010, 37, 987-992.	1.0	54
49	Systemic sclerosis: Recent insights. <i>Joint Bone Spine</i> , 2015, 82, 148-153.	0.8	54
50	Cardiac Biomarkers in Systemic Sclerosis: Contribution of High-Sensitivity Cardiac Troponin in Addition to N-Terminal Pro-Brain Natriuretic Peptide. <i>Arthritis Care and Research</i> , 2015, 67, 1022-1030.	1.5	54
51	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?âMTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019, 8, 515.	1.0	54
52	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. <i>Arthritis and Rheumatism</i> , 2011, 63, 2790-2796.	6.7	53
53	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 737-745.	0.5	53
54	Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 394-399.	0.5	53

#	ARTICLE	IF	CITATIONS
55	Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. <i>Arthritis Care and Research</i> , 2012, 64, 1244-1249.	1.5	53
56	S100A4 amplifies TGF- β 2-induced fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1748-1755.	0.5	52
57	OX40L blockade protects against inflammation-driven fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3901-10.	3.3	50
58	New therapeutic strategies in the management of systemic sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 607-615.	0.9	49
59	Recommendations for using TNF \pm antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. <i>Joint Bone Spine</i> , 2013, 80, 574-581.	0.8	48
60	Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1695-1696.	0.5	46
61	Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 62-69.	0.6	46
62	Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1801-1807.	1.0	46
63	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2091-2096.	6.7	45
64	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009, 36, 2356-2361.	1.0	43
65	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	2.5	43
66	Endothelial progenitor cells and rheumatic disorders. <i>Joint Bone Spine</i> , 2008, 75, 131-137.	0.8	42
67	Trabecular Bone Score in Female Patients with Systemic Sclerosis: Comparison with Rheumatoid Arthritis and Influence of Glucocorticoid Exposure. <i>Journal of Rheumatology</i> , 2015, 42, 228-235.	1.0	42
68	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	2.2	42
69	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 191-197.	0.5	41
70	Identification of NF- κ B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	1.6	41
71	Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 480-491.	1.6	41
72	Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity. <i>Arthritis Research and Therapy</i> , 2010, 12, R27.	1.6	40

#	ARTICLE	IF	CITATIONS
73	Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro-Osteolysis in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 366-373.	1.5	40
74	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 197.	1.6	40
75	Management recommendations for knee osteoarthritis: How usable are they?. <i>Joint Bone Spine</i> , 2010, 77, 458-465.	0.8	38
76	Tribbles homologue 3 stimulates canonical TGF- β 2 signalling to regulate fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 609-616.	0.5	38
77	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1541-1549.	0.5	38
78	Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. <i>Journal of Rheumatology</i> , 2010, 37, 105-115.	1.0	37
79	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	1.2	37
80	Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 997-1003.	1.0	35
81	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1089-1098.	0.5	35
82	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1360-1363.	0.5	34
83	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.5	31
84	Systemic sclerosis: Recent insight in clinical management. <i>Joint Bone Spine</i> , 2020, 87, 293-299.	0.8	31
85	Clinicogenomic factors of bioterapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
86	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1178-1182.	0.5	30
87	Targeting Costimulatory Pathways in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 2998.	2.2	30
88	Systemic sclerosis pathogenesis: contribution of recent advances in genetics. <i>Current Opinion in Rheumatology</i> , 2020, 32, 505-514.	2.0	30
89	Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1449-1456.	1.6	29
90	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. <i>Lancet Rheumatology</i> , The, 2022, 4, e8-e11.	2.2	29

#	ARTICLE	IF	CITATIONS
91	Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease. <i>Arthritis Care and Research</i> , 2016, 68, 1021-1027.	1.5	28
92	Is There a Place for Chimeric Antigen Receptorâ€”T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1954-1965.	2.9	28
93	Association between rheumatoid arthritis and primary biliary cirrhosis. <i>Joint Bone Spine</i> , 2007, 74, 279-281.	0.8	27
94	Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitorâ€”derived endothelial cells. <i>Arthritis and Rheumatism</i> , 2011, 63, 3552-3562.	6.7	26
95	Brief Report: A Regulatory Variant in <i>CCR6</i> Is Associated With Susceptibility to Antitopoisomeraseâ€”Positive Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 3202-3208.	6.7	26
96	Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. <i>PLoS ONE</i> , 2020, 15, e0232978.	1.1	26
97	Efficacy of joint lavage in knee osteoarthritis: meta-analysis of randomized controlled studies. <i>Rheumatology</i> , 2010, 49, 334-340.	0.9	25
98	Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 537-543.	1.6	25
99	Soluble CD163 as a Potential Biomarker in Systemic Sclerosis. <i>Disease Markers</i> , 2018, 2018, 1-5.	0.6	25
100	Familial Autoimmunity in Systemic Sclerosis â€” Results of a French-based Case-Control Family Study. <i>Journal of Rheumatology</i> , 2012, 39, 532-538.	1.0	24
101	Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts. <i>Journal of Rheumatology</i> , 2013, 40, 1706-1711.	1.0	23
102	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 439-445.	1.6	23
103	Association Study of <i>ITGAM</i> , <i>ITGAX</i> , and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	1.0	22
104	Mouse Model of Experimental Dermal Fibrosis: The Bleomycin-Induced Dermal Fibrosis. <i>Methods in Molecular Biology</i> , 2014, 1142, 91-98.	0.4	22
105	Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. <i>Rheumatology</i> , 2011, 50, 1494-1504.	0.9	21
106	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.4	20
107	Outcome of Patients with Systemic Sclerosis in the Intensive Care Unit. <i>Journal of Rheumatology</i> , 2015, 42, 1406-1412.	1.0	19
108	Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. <i>Arthritis Research and Therapy</i> , 2013, 15, R165.	1.6	18

#	ARTICLE	IF	CITATIONS
109	Flare of calcinosis despite rituximab therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, e5-e6.	1.6	18
110	Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients. <i>Rheumatology</i> , 2022, 61, SI163-SI168.	0.9	18
111	Experimental models of dermal fibrosis and systemic sclerosis. <i>Joint Bone Spine</i> , 2013, 80, 23-28.	0.8	17
112	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	2.9	17
113	¹⁸ F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.5	17
114	Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study. <i>Rheumatology</i> , 2022, 61, 2755-2769.	0.9	17
115	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. <i>International Journal of Cardiology</i> , 2016, 223, 385-389.	0.8	16
116	Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians. <i>Journal of Rheumatology</i> , 2009, 36, 337-340.	1.0	15
117	Estrogens Counteract the Profibrotic Effects of TGF- β 2 and their Inhibition Exacerbates Experimental Dermal Fibrosis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 593-601.e7.	0.3	15
118	Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1579-1588.	2.9	15
119	Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. <i>Journal of Rheumatology</i> , 2008, 35, 643-9.	1.0	15
120	Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models. <i>Journal of Inflammation</i> , 2015, 12, 9.	1.5	14
121	Updates on animal models of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 266-276.	1.0	14
122	The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor β 2 and Contributes to the Development of Experimental Dermal Fibrosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3140-3150.	2.9	13
123	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1681-1685.	0.5	13
124	Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 891-900.	0.5	13
125	Ethnic influence on the phenotype of French patients with systemic sclerosis. <i>Joint Bone Spine</i> , 2021, 88, 105081.	0.8	13
126	Driving Role of Interleukin-2-Related Regulatory γ CD4 + T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1387-1398.	2.9	13

#	ARTICLE	IF	CITATIONS
127	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
128	Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1339-1347.	1.6	12
129	Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 35-42.	0.4	12
130	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	0.9	11
131	Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses. <i>RMD Open</i> , 2022, 8, e002308.	1.8	11
132	Dermal tissue and cellular expression of fibrillin-1 in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2010, 49, 657-661.	0.9	10
133	Association of Metalloproteinase Gene Polymorphisms with Systemic Sclerosis in the European Caucasian Population. <i>Journal of Rheumatology</i> , 2010, 37, 599-602.	1.0	10
134	Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations. <i>Journal of Rheumatology</i> , 2010, 37, 1164-1167.	1.0	10
135	Small, medium but not large arteries are involved in digital ulcers associated with systemic sclerosis. <i>Joint Bone Spine</i> , 2016, 83, 444-447.	0.8	10
136	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. <i>Rheumatology</i> , 2017, 56, 1874-1883.	0.9	10
137	Influence of perceived barriers and facilitators for physical activity on physical activity levels in patients with rheumatoid arthritis or spondyloarthritis: a cross-sectional study of 150 patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 915.	0.8	10
138	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	0.9	10
139	Severe Refractory Rheumatoid Arthritis Successfully Treated with Combination Rituximab and Anti-Tumor Necrosis Factor-Î±-Blocking Agents. <i>Journal of Rheumatology</i> , 2009, 36, 2125.2-2126.	1.0	9
140	Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 163-164.	0.4	9
141	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011, 13, 114.	1.6	8
142	All-cause Mortality Associated with TNF-Î± Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Medicine</i> , 2015, 128, 1367-1373.e1.	0.6	8
143	Prevalence and Disease-specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. <i>Arthritis Care and Research</i> , 2018, 70, 1218-1227.	1.5	7
144	Erosive arthritis autoantibodies in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151947.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Targeted immunotherapies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 165-72.	0.4	7
146	Arthrose du genou et de la hanche et activit��: revue syst��matique internationale et synth��se (OASIS). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2006, 73, 736-752.	0.0	6
147	Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellis��es par la Haute Autorit�� de sant�� fran��saise. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 459-466.	0.0	6
148	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. <i>Arthritis Research and Therapy</i> , 2022, 24, 13.	1.6	6
149	Performance of Skin Ultrasound to Measure Skin Involvement in Different Animal Models of Systemic Sclerosis. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 845-852.	0.7	5
150	Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 149-159.	1.0	5
151	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	1.3	5
152	Influence of inflammatory and non-inflammatory rheumatic disorders on the clinical and biological profile of type-2 diabetes. <i>Rheumatology</i> , 2021, 60, 3598-3606.	0.9	5
153	Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151951.	1.6	5
154	From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 82-87.	0.4	5
155	Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011, 38, 2419-2427.	1.0	4
156	Disease Activity Score in 28 Joints Using GGT Permits a Dual Evaluation of Joint Activity and Cardiovascular Risk. <i>Journal of Rheumatology</i> , 2020, 47, 1738-1745.	1.0	4
157	To apply the recent EULAR recommendations, more knowledge on adherence patterns to medication and to physical activity is needed. <i>Joint Bone Spine</i> , 2021, 88, 105137.	0.8	3
158	Editorial: Key Players in Systemic Sclerosis: The Immune System and Beyond. <i>Frontiers in Immunology</i> , 2021, 12, 770419.	2.2	3
159	Association study of CRP gene in systemic sclerosis in European Caucasian population. <i>Rheumatology International</i> , 2014, 34, 389-392.	1.5	2
160	Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0203607.	1.1	2
161	Rapidly Progressive Systemic Sclerosis-associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Gu��rin Therapy for Early-stage Bladder Cancer. <i>Journal of Rheumatology</i> , 2021, 48, 1348-1349.	1.0	2
162	An update on recent randomized clinical trials in systemic sclerosis. <i>Joint Bone Spine</i> , 2021, 88, 105184.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Association polyarthrite rhumatoïde et cirrhose biliaire primitive. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 rgBT /Overlock	0.0	1
164	Intestin des connectivites et vascularites. Revue Du Rhumatisme Monographies, 2016, 83, 249-255.	0.0	1
165	Anticoagulation in Autoimmune Rheumatic Diseases. , 2020, , 159-179.		1
166	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 43-48.	0.4	1
167	Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection. Rheumatology, 2022, , .	0.9	1
168	Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders. Current Rheumatology Reviews, 2007, 3, 95-101.	0.4	0
169	Sclérodémie systémique: État des lieux en 2008. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 918-924.	0.0	0
170	Tendons, Joints, and Bone. , 2012, , 531-545.		0
171	Recommandations pour le traitement de l'arthrose du genou: sont-elles applicables?. Kinesithérapie, 2012, 12, 28-39.	0.0	0
172	Reply. Arthritis Care and Research, 2013, 65, 1016-1016.	1.5	0
173	Systemic Sclerosis-related Acute Myocardial Infarction: Definition. American Journal of Medicine, 2014, 127, e37.	0.6	0
174	Reports from the 2015 American College of Rheumatology Congress. Journal of Scleroderma and Related Disorders, 2016, 1, 16-20.	1.0	0
175	SAT0038...SEMAPHORINS: FROM ANGIOGENESIS TO INFLAMMATION IN RHEUMATOID ARTHRITIS. , 2019, , .		0
176	SAT0254...VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
177	Données récentes sur la prise en charge clinique de la sclérodémie systémique. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 24-31.	0.0	0
178	Cellules CAR-T: extension aux maladies auto-immunes en rhumatologie. Revue Du Rhumatisme (Edition) Tj ETQq0 0.0 rgBT /Overlock 1	0.0	0
179	Revue des récents essais randomisés dans la sclérodémie systémique. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.0	0
180	Tendons, Joints, and Bone. , 2017, , 507-523.		0

#	ARTICLE	IF	CITATIONS
181	The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110666.	1.2	0
182	Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0